XML 143 R92.htm IDEA: XBRL DOCUMENT
v3.23.4

Strategic License Agreements - Narrative (Details) |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Mar. 21, 2021 USD ($) | Sep. 30, 2021 USD ($) | Jul. 31, 2021 USD ($) | Jun. 30, 2021 USD ($) | Jan. 31, 2017 USD ($) LICENSEAGREEMENT | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Mar. 31, 2021 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) $ / LICENSEAGREEMENT $ / shares | Dec. 31, 2022 USD ($) $ / LICENSEAGREEMENT € / shares | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | $ 0 | $ 174,000 |  | $ 886,000 | $ 2,161,000 | $ 2,329,000 |  | $ 18,739,000 | $ 0
Deferred revenue |  |  |  |  |  | 0 |  |  | 0 |  | 2,696,000 | $ 2,696,000 |  |
Contract liabilities |  |  |  |  |  |  |  |  |  |  | 2,696,000 | 2,696,000 | 3,576,000 | 0
Contract assets |  |  |  |  |  | 0 | 0 |  | 0 | 0 | 0 | 0 | 0 | 0
Current deferred revenue |  |  |  |  |  | 0 |  |  | 0 |  | 517,000 | 517,000 | 2,359,000 |
Number of license agreements | LICENSEAGREEMENT |  |  |  |  | 1 |  |  |  |  |  |  |  |  |
License |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  | 0 |  | 12,000,000 | 0
Immedica Pharma AB |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non refundable payment received | $ 21,500,000 |  |  |  |  |  |  | $ 21,500,000 |  |  |  |  |  |
Percentage of payment for cost incurred in PIP trial | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Rate of revenue share |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |
Reimbursement |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ 21,500,000 |  |  |  |  |  |  | $ 21,500,000 |  |  |  |  |  |
Estimated amount incurred |  |  | 3,600,000 |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  | 25,100,000 |  |  |  |  |  |  |  |  |  |  |
Allocation price net |  |  | 12,000,000 |  |  |  |  | 12,000,000 |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  | 3,600,000 | 3,600,000 |  |
Contract liabilities |  |  |  |  |  | 0 |  |  | 0 |  | 2,400,000 | 2,400,000 |  |
License and supply agreement date | Mar. 21, 2021 |  |  |  |  |  |  |  |  |  |  |  |  |
Additional upfront payment to be received |  |  |  |  |  |  |  | 120,800,000 |  |  |  |  |  |
Total deferred revenue |  |  |  |  |  |  |  |  |  |  | 2,700,000 | 2,700,000 | 3,600,000 |
Current deferred revenue |  |  |  |  |  |  |  |  |  |  | 500,000 | $ 500,000 | 2,400,000 |
Immedica Pharma AB | License |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Full reimbursement of costs included in upfront fixed payment received | $ 1,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Immedica Pharma AB | PEACE Trial and BLA Package |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Allocated amount of transaction price |  |  | 9,600,000 |  |  |  |  | 9,600,000 |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | $ 200,000 |  |  | $ 2,200,000 | $ 2,300,000 |  | 6,700,000 |
Immedica Pharma AB | PIP Trial |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Allocated amount of transaction price |  |  | $ 3,500,000 |  |  |  |  | $ 3,500,000 |  |  |  |  |  |
Immedica Pharma AB | License Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  | $ 12,000,000 |  | $ 12,000,000 |  |  |  |  |  |  |  |  | 12,000,000 | 0
Immedica Pharma AB | Peace Phase 3 Trial and Drug Supply |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | $ 0 |  |  | $ 900,000 |  |  |  |  |
Immedica Pharma AB | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of payment for cost incurred in PIP trial |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |
Costs incurred in performing PIP Trial | $ 1,800,000 |  |  |  |  |  |  | $ 1,800,000 |  |  |  |  |  |
Milestone payments exchange rate | € / shares |  |  |  |  |  |  |  |  |  |  |  | $ 1 |  |
Immedica Pharma AB | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments exchange rate | $ / shares |  |  |  |  |  |  |  |  |  |  | $ 1.07 |  |  |
University of Texas at Austin | License Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research agreement date |  |  |  |  |  |  |  |  |  |  | 2013-12 |  |  |
Number of license agreements | $ / LICENSEAGREEMENT |  |  |  |  |  |  |  |  |  |  | 2 | 2 |  |
Maximum future contingent license payment |  |  |  |  | $ 6,400,000 |  |  |  |  |  |  |  |  |
Aggregate potential milestone payments for receipt of regulatory approval |  |  |  |  | 5,000,000 |  |  |  |  |  |  |  |  |
Aggregate potential milestone payments for final regulatory approval of second indication |  |  |  |  | $ 500,000 |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  |  |  |  | $ 100,000 |  |  |
Annual license fees paid |  |  |  |  |  |  |  |  |  |  |  |  | $ 100,000 | $ 100,000
University of Texas at Austin | Maximum | License Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Rate of revenue share |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |
University of Texas at Austin | Minimum | License Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Rate of revenue share |  |  |  |  | 6.50% |  |  |  |  |  |  |  |  |

X
- Definition Additional upfront payment ability to received. + References No definition available. + Details
Name: | agle_AdditionalUpfrontPaymentAbilityToReceived
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate potential milestone payments for final regulatory approval of second indication. + References No definition available. + Details
Name: | agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate potential milestone payments for receipt of regulatory approval. + References No definition available. + Details
Name: | agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Allocated amount of transaction price. + References No definition available. + Details
Name: | agle_AllocatedAmountOfTransactionPrice
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Allocation price total. + References No definition available. + Details
Name: | agle_AllocationPriceTotal
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contract With Customer, Full Reimbursement Of Costs Included Liability + References No definition available. + Details
Name: | agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Costs incurred in performing the pip trial. + References No definition available. + Details
Name: | agle_CostsIncurredInPerformingTheTrial
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License and supply agreement date. + References No definition available. + Details
Name: | agle_LicenseAndSupplyAgreementDate
Namespace Prefix: | agle_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum future contingent license payment. + References No definition available. + Details
Name: | agle_MaximumFutureContingentLicensePayment
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments exchange rate. + References No definition available. + Details
Name: | agle_MilestonePaymentsExchangeRate
Namespace Prefix: | agle_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non refundable payment received. + References No definition available. + Details
Name: | agle_NonRefundablePaymentReceived
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of license agreements. + References No definition available. + Details
Name: | agle_NumberOfLicenseAgreements
Namespace Prefix: | agle_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Payment of annual license fees. + References No definition available. + Details
Name: | agle_PaymentOfAnnualLicenseFees
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment of milestone. + References No definition available. + Details
Name: | agle_PaymentOfMilestone
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of payment for cost incurred in pip trial. + References No definition available. + Details
Name: | agle_PercentageOfPaymentForCostIncurredInPIPTrial
Namespace Prefix: | agle_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Rate of revenue share. + References No definition available. + Details
Name: | agle_RateOfRevenueShare
Namespace Prefix: | agle_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research agreement date. + References No definition available. + Details
Name: | agle_ResearchAgreementDate
Namespace Prefix: | agle_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment. + References No definition available. + Details
Name: | agle_UpfrontPayment
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition A payment from an investee, in which the investment basis has previously been reduced to zero. This amount reduces net cash used in operating activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_ReimbursementFromLimitedPartnershipInvestment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of transactions with related party during the financial reporting period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3 + Details
Name: | us-gaap_RelatedPartyTransactionAmountsOfTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=agle_ImmedicaPharmaABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=agle_PeaceTrialAndBLAPackageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=agle_PIPTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=agle_LicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=agle_PeacePhase3TrialAndDrugSupplyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=agle_UniversityOfTexasAtAustinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |